Фибромиалгия: новое о международных критериях диагностики и тактики ведения пациентов
- Авторы: Колоколов О.В.1, Колоколова А.М.1, Ситкали И.В.1
-
Учреждения:
- ФГБОУ ВО «Саратовский государственный медицинский университет им. В.И. Разумовского»
- Выпуск: № 5 (2017)
- Страницы: 94-104
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2412-4036/article/view/279038
- ID: 279038
Цитировать
Полный текст
![Открытый доступ](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Аннотация
В статье обсуждается актуальная проблема дифференциальной диагностики заболеваний, проявляющихся синдромом фибромиалгии. Перечислены «старые» и новые критерии клинической диагностики фибромиалгии. Подчеркнуто, что грамотная клиническая оценка для уточнения причин болевого синдрома имеет большее значение, нежели дополнительная диагностика. Диагноз ФМ может быть установлен в условиях учреждений, оказывающих первичную медико-санитарную помощь, на основании оценки соответствия критериям The American College of Rheumatology (ACR, 2010 г.) при условии нормальных результатов объективного осмотра и рутинных лабораторных тестов, исключающих другие заболевания. Указаны основные группы заболеваний, которые надо иметь в виду во время диагностического поиска при подозрении на фибромиалгию: болезни костно-мышечной системы и соединительной ткани, эндокринологические, гастроэнтерологические, инфекционные, онкологические заболевания, неврологические расстройства, нарушения психического здоровья, ятрогенная боль. Особое внимание уделено анкилозирующему спондилоартриту и миофасциальному болевому синдрому. Обсуждаются проблемы лечения фибромиалгии. Описаны свойства флупиртина (препарат Нолодатак®), позволяющие использовать его в сложных диагностических ситуациях, когда невозможно быстро установить точный нозологический диагноз заболевания, проявляющегося болевым синдромом.
Ключевые слова
Полный текст
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Об авторах
Олег Владимирович Колоколов
ФГБОУ ВО «Саратовский государственный медицинский университет им. В.И. Разумовского»
Email: kolokolov@inbox.ru
д.м.н., заведующий кафедрой неврологии ИДПО им. К.Н. Третьякова
Анжелика Михайловна Колоколова
ФГБОУ ВО «Саратовский государственный медицинский университет им. В.И. Разумовского»
Email: kolokolov@inbox.ru
к.м.н., ассистент кафедры нервных болезней
Инна Вадимовна Ситкали
ФГБОУ ВО «Саратовский государственный медицинский университет им. В.И. Разумовского»
Email: kolokolov@inbox.ru
аспирант кафедры неврологии ИДПО им. К.Н. Третьякова
Список литературы
- Ablin J.N., Amital H., Ehrenfeld M. et al. Guidelines for the diagnosis and treatment of the fibromyalgia syndrome [in Hebrew] // Harefuah. 2013; 152: 742-747,751,750.
- Eich W., Hauser W., Arnold B. et al. Fibromyalgia syndrome. Definition, classification, clinical diagnosis and prognosis [in German] // Schmerz. 2012; 26: 247-258.
- Fitzcharles M.A., Ste-Marie P.A., Goldenberg D.L. et al. Canadian Pain Society and Canadian Rheumatology Association recommendations for rational care of persons with fibromyalgia. A summary report // J Rheumatol. 2013; 40: 1388-1393.
- Macfarlane G.J., Kronisch C., Dean L.E. et al. EULAR revised recommendations for the management of fibromyalgia // Ann Rheum Dis. 2017; 76: 318-328.
- Wolfe F., Walitt B. Fibromyalgia is over-diagnosed in the general population // Arthritis Rheumatol. 2016; 68: 3043-3044.
- Marques A.P., Santo A.S., Berssaneti A.A. et al. Prevalence of fibromyalgia: literature review update // Rev Bras Reumatol. 2016; pii: S0482-5004(16)30174-7.
- Стороженко О.Н., Лесник О.М., Макбет Д., Макфарлайи Г. Хроническая генерализованная боль в теле: частота в популяции и связь с ментальными расстройствами личности. Научно-практическая ревматология. 2002 ; 2:54. [Storozhenko O.N., Lesnik O.M., Makbet D., Makfarlayi G. Chronic generalized body pain: frequency in the population and the relationship with mental disorders personality. Scientific-practical rheumatology. 2002;2:54 (in Russ.)]
- Hauser W., Perrot S., Sommer C. et al. Diagnostic confounders of chronic widespread pain: not always fibromyalgia // PAIN Reports. 2017; 2(3): e598.
- Wolfe F., Smythe H.A., Yunus M.B. et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee // Arthritis Rheum. 1990; 33(2): 160-172.
- Данилов А.Б. Диагностика и лечение фибромиалгии. Лечащий врач. 2012;5:30-4. [Danilov A.B. Diagnosis and treatment of fibromyalgia. Doctor. 2012;5:30-4 (in Russ.)]
- Wolfe F., Clauw D.J., Fitzcharles M.A. et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity // Arthritis Care Res (Hoboken). 2010; 62(5): 600-610.
- Wolfe F., Clauw D.J., Fitzcharles M.A. et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia // J Rheumatol. 2011; 38(6): 11 13-1122.
- Wolfe F. Editorial: the status of fibromyalgia criteria // Arthritis Rheumatol. 2015; 67(2): 330-333.
- Wolfe F., Fitzcharles M.A., Goldenberg D.L. et al. Comparison of Physician-Based and Patient-Based Criteria for the Diagnosis of Fibromyalgia // Arthritis Care Res (Hoboken). 2016; 68(5): 652-659.
- Fitzcharles M.A., Boulos P. Inaccuracy in the diagnosis of fibromyalgia syndrome: analysis of referrals // Rheumatology (Oxford). 2003; 42: 263-267.
- Fitzcharles M.A., Esdaile J.M. The overdiagnosis of fibromyalgia syndrome // Am J Med. 1997; 103: 44-50.
- Perrot S., Dieude P., Perocheau D., Allanore Y. Comparison of pain, pain burden, coping strategies, and attitudes between patients with systemic sclerosis and patients with rheumatoid arthritis: a cross-sectional study // Pain Med. 2013; 14: 1776-1785.
- Ablin J.N., Eshed I., Berman M. et al. Prevalence of axial spondyloarthropathy among patients suffering from fibromyalgia - an MRI study with application of the ASAS classification criteria // Arthritis Care Res (Hoboken). 2016. doi: 10.1002/acr.22967.
- Baraliakos X., Maksymowych W.P. Imaging in the diagnosis and management of axial spondyloarthritis // Best Pract Res Clin Rheumatol. 2016; 30: 608-623.
- Roussou E., Ciurtin C. Clinical overlap between fibromyalgia tender points and enthesitis sites in patients with spondyloarthritis who present with inflammatory back pain // Clin Exp Rheumatol. 2012; 30(6 suppl 74): 24-30.
- Sepriano A., Landewe R., van der Heijde D. et al. Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis // Ann Rheum Dis. 2016; 75: 1034-1042.
- Tough E.A., White A.R., Richards S., Campbell J. Variability of criteria used to diagnose myofascial trigger point pain syndrome - evidence from a review of the literature // Clin J Pain. 2007; 23: 278-286.
- Clauw D.J. Fibromyalgia: a clinical review // JAMA. 2014; 31 1: 1547-1555.
- Fernandez de Las Penas C., Arendt-Nielsen L. Myofascial pain and fibromyalgia: two different but overlapping disorders // Pain Manag. 2016; 6: 401-408.
- Ge H.Y., Wang Y., Danneskiold-Samsoe B. et al. The predetermined sites of examination for tender points in fibromyalgia syndrome are frequently associated with myofascial trigger points // J Pain. 2010; 11: 644-651.
- Schneider M.J. Tender points/fibromyalgia vs. trigger points/myofascial pain syndrome: a need for clarity in terminology and differential diagnosis // J Manipulative Physiol Ther. 1995; 18: 398-406.
- Ahmad J., Tagoe C.E. Fibromyalgia and chronic widespread pain in autoimmune thyroid disease // Clin Rheumatol. 2014; 33: 885-891.
- Wintermeyer E., Ihle C., Ehnert S. et al. Crucial role of vitamin D in the musculoskeletal system // Nutrients. 2016; 8: 319.
- Yong W.C., Sanguankeo A., Upala S. Effect of vitamin D supplementation in chronic widespread pain: a systematic review and meta-analysis // Clin Rheumatol. 2017. doi: 10.1007/s10067-017-3754-y.
- Aziz I., Dwivedi K., Sanders D.S. From coeliac disease to noncoeliac gluten sensitivity; should everyone be gluten free? // Curr Opin Gastroenterol. 2016; 32: 120-127.
- Hsu V.M., Patella S.J., Sigal L.H. «Chronic Lyme disease» as the incorrect diagnosis in patients with fibromyalgia // Arthritis Rheum. 1993; 36: 1493-1500.
- Kozanoglu E., Canataroglu A., Abayli B. et al. Fibromyalgia syndrome in patients with hepatitis C infection // Rheumatol Int. 2003; 23: 248-251.
- Wormser G.P., Weitzner E., McKenna D. et al. Long-term assessment of fibromyalgia in patients with culture-confirmed Lyme disease // Arthritis Rheumatol. 2014; 67: 837-839.
- Burgstaller J.M., Schuffler P.J., Buhmann J.M. et al. Is there an association between pain and magnetic resonance imaging parameters in patients with lumbar spinal stenosis? // Spine (Phila Pa 1976). 2016; 41: E1053-1062.
- Mader R., Novofastovski I., Rosner E. et al. Nonarticular tenderness and functional status in patients with diffuse idiopathic skeletal hyperostosis // J Rheumatol. 2010; 37: 1911-1916.
- Mader R., Verlaan J.J., Buskila D. Diffuse idiopathic skeletal hyperostosis: clinical features and pathogenic mechanisms // Nat Rev Rheumatol. 2013; 9: 741-750.
- Gesquiere-Dando A., Attarian S., Maues De Paula A. et al. Fibromyalgia-like symptoms associated with irritable bowel syndrome: a challenging diagnosis of late-onset Pompe disease // Muscle Nerve. 2015; 52: 300-304.
- Lucia A., Nogales-Gadea G., Perez M. et al. McArdle disease: what do neurologists need to know? // Nat Clin Pract Neurol. 2008; 4: 568-577.
- Bays H. Statin safety: an overview and assessment of the data - 2005 // Am J Cardiol. 2006; 97: 6C-26C.
- Mosshammer D., Schaeffeler E., Schwab M., Morike K. Mechanisms and assessment of statin-related muscular adverse effects // Br J Clin Pharmacol. 2014; 78: 454-466.
- Rabar S., Harker M., O'Flynn N., Wierzbicki A.S. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance // BMJ. 2014; 349: g4356.
- Harris R.E., Clauw D.J., Scott D.J. et al. Decreased central mu-opioid receptor availability in fibromyalgia // J Neurosci. 2007; 27: 10000-6.
- Hayhurst C.J., Durieux M.E. Differential opioid tolerance and opioid-induced hyperalgesia: a clinical reality // Anesthesiology. 2016; 124: 483-488.
- Borrie A.E., Kim R.B. Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers // Expert Opin Drug Metab Toxicol. 2017; 13: 149-156.
- Laroche F., Coste J., Medkour T. et al. Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study // J Pain. 2014; 15: 293-303.
- Clark D.W., Strandell J. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? // Eur J Clin Pharmacol. 2006; 62: 473-479.
- Bello N., Etcheto A., Beal C. et al. Evaluation of the impact of fibromyalgia in disease activity and treatment effect in spondyloarthritis // Arthritis Res Ther. 2016; 18: 42.
- Wolfe F., Clauw D.J., Fitzcharles M.A. et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia // J Rheumatol. 2011; 38: 1113-1122.
- Defazio G., Berardelli A., Fabbrini G. et al. Pain as a nonmotor symptom of Parkinson disease: evidence from a casecontrol study // Arch Neurol. 2008; 65: 1191-1194.
- Negre-Pages L., Regragui W., Bouhassira D. et al. Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey // Mov Disord. 2008; 23: 1361-1369.
- Toda K., Harada T. Prevalence, classification, and etiology of pain in Parkinson's disease: association between Parkinson's disease and fibromyalgia or chronicwidespread pain // Tohoku J ExpMed. 2010; 222: 1 -5.
- Yilmaz U., Bird T.T., Carter G.T. et al. Pain in hereditary neuropathy with liability to pressure palsy: an association with fibromyalgia syndrome? // Muscle Nerve. 2015; 51: 385-390.
- Caro X.J., Winter E.F. The role and importance of small fiber neuropathy in fibromyalgia pain // Curr Pain Headache Rep. 2015; 19: 55.
- Uceyler N., Sommer C. Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia // PAIN. 2013; 154: 2569.
- Uceyler N., Zeller D., Kahn A.K. et al. Small fibre pathology in patients with fibromyalgia syndrome // Brain. 2013; 136(pt 6): 1857-1867.
- Perovic S., Pialoglou P., Schroder H.C. et al. Flupirtine increases the levels of glutathione and Bc1-2 in hNT (human Ntera/D1) neurons: mode of action of the drug-mediated anti-apoptotic effect // Eur J Pharmacol. 1996; 12: 157-164.
- Jakob R., Krieglsteinet J. Influence of flupirtine on a G-protein coupled inwardly rectifying potassium current in hippocampal neurons // Br J Pharmacol. 1997; 122: 1333-1338.
- Sampath D., Valdez R., White A.M., Raol Y.H. Anticonvulsant effect of flupirtine in an animal model of neonatal hypoxic-ischemic encephalopathy // Neuropharmacology. 2017; 123: 126-135.
- Worz R. Flupirtine in chronic myofascial pain conditions // Fortschr Med. 1991; 109 (6): 158-160.
- Stoll A.L. Fibromyalgia symptoms relieved by flupirtine: an open-label case series // Psychosomatics. 2000; 41(4): 371-372.
- Uberall M.A., Mueller-Schwefe G.H., Terhaag B.Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study // Curr Med Res Opin. 2012; 28(10): 1617-1634.
- Ueberall M.A., Mueller-Schwefe G.H., Terhaag B. Efficacy and tolerability of flupirtine in subacute/ chronic musculoskeletal pain - results of a patient level, pooled re-analysis of randomized, double-blind, controlled trials // Int J Clin Pharmacol Ther. 2011; 49(1 1): 637-647.
- Devulder J. Flupirtine in pain management: pharmacological properties and clinical use // CNS Drugs. 2010; 24(10): 867-881.
Дополнительные файлы
![](/img/style/loading.gif)